127 related articles for article (PubMed ID: 2091505)
1. Experimental design for the evaluation of the antitumor action of cytokines.
Ciolli V; Sestili P; Brigato M; Gabriele L; Varano F; Locardi C; Belardelli F
Ann Ist Super Sanita; 1990; 26(3-4):441-51. PubMed ID: 2091505
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells.
Santodonato L; Ferrantini M; Palombo F; Aurisicchio L; Delmastro P; La Monica N; Di Marco S; Ciliberto G; Du MX; Taylor MW; Belardelli F
Cancer Gene Ther; 2001 Jan; 8(1):63-72. PubMed ID: 11219495
[TBL] [Abstract][Full Text] [Related]
3. The relevance of animal tumour models to the preclinical screening of cytokines.
Kelly SA; Malik ST; Balkwill FR
Cancer Surv; 1989; 8(4):741-54. PubMed ID: 2484311
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
Tahara H; Lotze MT
Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935
[TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of a metastatic Eb-like tumor variant highly responsive to interleukin (IL)-2 and to combination cytokine therapy with IL-2/IL-1 beta and IL-1 beta/interferon-alpha/beta.
Gabriele L; Proietti E; Greco G; Venditti M; Gresser I; Schirrmacher V; Von Hoegen P; Testa U; Modesti A; Cianfriglia M
Invasion Metastasis; 1993; 13(3):147-62. PubMed ID: 8112975
[TBL] [Abstract][Full Text] [Related]
6. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
7. The tumor-cytokine transplantation assay and the antitumor activity of interleukin-4.
Tepper RI
Bone Marrow Transplant; 1992; 9 Suppl 1():177-81. PubMed ID: 1504664
[No Abstract] [Full Text] [Related]
8. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
9. Perilymphatic injections of cytokines: a new tool in active cancer immunotherapy. Experimental rationale and clinical findings.
Forni G; Giovarelli M; Jemma C; Bosco MC; Caretto P; Modesti A; Santoni A; Forni M; Cortesina G; de Stefani A
Ann Ist Super Sanita; 1990; 26(3-4):397-409. PubMed ID: 2151108
[TBL] [Abstract][Full Text] [Related]
10. Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells.
Ferrantini M; Proietti E; Santodonato L; Gabriele L; Peretti M; Plavec I; Meyer F; Kaido T; Gresser I; Belardelli F
Cancer Res; 1993 Mar; 53(5):1107-12. PubMed ID: 8439955
[TBL] [Abstract][Full Text] [Related]
11. [Preclinical evaluation of anticancer drugs: a model remaining a model!].
Lavelle F
Bull Cancer; 1998 Oct; 85(10):837-42. PubMed ID: 9835860
[TBL] [Abstract][Full Text] [Related]
12. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Hoffman RM
Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models.
Breistøl K; Balzarini J; Sandvold ML; Myhren F; Martinsen M; De Clercq E; Fodstad O
Cancer Res; 1999 Jun; 59(12):2944-9. PubMed ID: 10383159
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes.
Fox BA; Spiess PJ; Kasid A; Puri R; Mulé JJ; Weber JS; Rosenberg SA
J Biol Response Mod; 1990 Oct; 9(5):499-511. PubMed ID: 2174966
[TBL] [Abstract][Full Text] [Related]
15. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
17. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
Xiang J
Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
[TBL] [Abstract][Full Text] [Related]
18. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
19. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
20. Are syngeneic mouse tumor models still valuable experimental models in the field of anti-cancer drug discovery?
Darro F; Decaestecker C; Gaussin JF; Mortier S; Van Ginckel R; Kiss R
Int J Oncol; 2005 Sep; 27(3):607-16. PubMed ID: 16077908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
